PMCB (35) CRIS (27) LIMN (34) SCNI (29) ⌘ Pro Terminal →

Calidi Biotherapeutics Inc. (CLDI) — RQD Stock Rating Cockpit

Q: Should I buy, hold, or sell CLDI stock right now?

Calidi Biotherapeutics Inc. (CLDI) currently earns a Roarable Rating of E (Strong Sell — SELL) with 31/100 RQD Confidence. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

Q: What is CLDI's 12-month price target and RQD AI Jury consensus?

CLDI's 12-month base price target is $0.61 (range $0.48 to $28.39), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

$0.69 +2.43% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.69

Calidi Biotherapeutics Inc. (CLDI) carries a Roarable Rating of E (Strong Sell) with 31/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (31/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $2.5M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on CLDI Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is CLDI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Calidi Biotherapeutics Inc. (NYSE: CLDI) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $0.69 (+2.43% 1D, market cap $2.5M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, CLDI ranks #837 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does CLDI compare to PMCB and CRIS in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), CLDI carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, PMCB (PharmaCyte Biotech Inc.) holds a D- grade (35/100 RQD, P/E N/A, ROIC -30.2%, cap $3.6M) and CRIS (Curis Inc.) posts a E grade (27/100 RQD, P/E N/A, ROIC -35.0%, cap $3.7M). Among the 5-stock peer group, CLDI leads on earnings multiple (N/A) while PMCB leads on capital efficiency (-30.2% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for CLDI?

▼

Per CLDI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001855485), Calidi Biotherapeutics Inc. generated $0 in revenue, -$19.9M in net income, and -$21.3M in free cash flow against $8.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $0.69 (+0.25%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (31/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.4% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-11.6% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CLDI)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (31/100 Composite)

🔍 WHY CLDI SCORES 31/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (32% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Macro Regime Fit+9/20 pts (29% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 27 (OVERSOLD (<32))

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$0.95-17.9% Next Q

Q2 (-2Q)

Grade E$0.78-17.9% Next Q

Q3 (-1Q)

Grade E$0.64+7.8% Next Q

Current

Grade E$0.69-9.4% Hist 90D α

Trajectory: E (39) → E (31)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a CLDI Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While CLDI currently carries a cautious 31/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.06) and Max Pain ($0.72) forces dealer call-delta covering toward $28.39.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CLDI• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “CLDI Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 31%NO 69%Trade / Inspect Odds →

RSI-14 MOMENTUMOVERSOLD (<32)

2730 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCOREWEAK QUALITY (1–4)

2 / 99-Pt Accounting

52-WEEK LASER RANGE2% OF RANGE

L: $1$0.69H: $27

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: ERQD 4 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 8 / 40

3. Hidden Risks & Market Weather● WARNING

SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: DRQD 19 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on CLDI

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (20)

-35.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BEARISH (50)

Altman-Z 4.20 and Piotroski 2/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (28)

8/40 institutional & smart-money positioning score with 9/20 macro alignment.

Bull Case: Why Buyers Like CLDI

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Sensitive to high interest rates and tighter Federal Reserve market liquidity.
!Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CLDI)

✓Walkthrough of CLDI's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

CLDI // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -79.65%⚡ TESTING RESISTANCE

2026-11-02O $0.70H $0.70L $0.67C $0.69VOL 20.9K

RES: $0.86SUP: $0.52SMA50: $1.06SMA200: $4.36

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CLDI Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CLDI Butterfly Map → + Track CLDI →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on CLDI today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CLDI. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for CLDI today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CLDI)

Health Care Rank #837 of 1016 ⚔️ PMCB vs CLDI Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CLDI vs. PMCB, CRIS, LIMN, SCNI)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Calidi Biotherapeutics Inc. (CLDI) ranks #837 by composite RQD confidence (31/100, grade E) and #987 by equity capitalization ($2.5M). Within this direct 5-issuer industry benchmark cohort, CLDI leads on earnings valuation at N/A trailing P/E, while PMCB leads on capital efficiency and profitability with -30.2% ROIC and — gross margin. PMCB currently holds the highest overall quantitative score in the immediate peer group at 35/100 (D-) compared with CLDI at 31/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
CLDI ACTIVE Calidi Biotherapeutics Inc.	E	31/100	—	—	-35.0%	+2.43%	$2.5M	Benchmark Subject
PMCB PharmaCyte Biotech Inc.	D-	35/100	—	—	-30.2%	-9.03%	$3.6M	/pmcb-vs-cldi →
CRIS Curis Inc.	E	27/100	—	—	-35.0%	+9.39%	$3.7M	/cris-vs-cldi →
LIMN Liminatus Pharma Inc. (Class A)	E	34/100	—	—	-35.0%	-2.59%	$3.9M	/limn-vs-cldi →
SCNI Scinai Immunotherapeutics Ltd.	E	29/100	—	-30.0%	-35.0%	-9.04%	$1.4M	/scni-vs-cldi →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001855485

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Calidi Biotherapeutics Inc. (CLDI) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$19.9M, operating cash flow of -$21.3M, and free cash flow of -$21.3M (-8.1% YoY). On the balance sheet, CLDI closed FY2025 with $8.9M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$19.9M	-$21.3M	-$21.3M	$8.9M	—
FY2024 (FY)	2024-12-31	$0	-$22.1M	-$19.7M	-$19.7M	$14.2M	—
FY2023 (FY)	2023-12-31	$0	-$29.2M	-$27.0M	-$27.0M	—	—

3. CLDI Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CLDI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does CLDI compare to PMCB and CRIS in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for CLDI?

Where is CLDI trading relative to its 50-day, 200-day, and 52-week technical levels?

CLDI last traded at $0.69 (+2.43% on volume of 48,422 shares), positioning the stock -34.91% below its 50-day simple moving average ($1.06) and -84.17% below its 200-day simple moving average ($4.36). Across its 52-week range of $0.62 to $27.04, CLDI sits at the 0.3% percentile with a 14-day RSI of 27.0 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.00 to $0.78).

CLDI Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell CLDI stock right now?

Calidi Biotherapeutics Inc. (CLDI) currently earns a Roarable Rating of E (Strong Sell — SELL) with 31/100 RQD Confidence. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

What is CLDI's 12-month price target and RQD AI Jury consensus?

CLDI's 12-month base price target is $0.61 (range $0.48 to $28.39), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: CLDI RQD Cockpit CLDI 12M Forecast CLDI Earnings & Move CLDI Dividends & DRIP CLDI Insiders & 13F CLDI Whale Options CLDI Profit Sankey CLDI News & Why

ROARABLE RATING BRIEF • RQD 31/100 (E) ✓ STAGE-C NUMBER FIREWALL VERIFIED

CLDI — Calidi Biotherapeutics Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:54:33Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, CLDI scores 31 out of 100 with a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are:

Fundamental Cash Engine: 4 / 20. Per the Roarable RQD rating, this reflects ROIC of -35% and FCF yield of 0%. For an investor, this means the business is not currently generating cash returns on capital, so the valuation case must rest on future events rather than present earnings power.
Whale 13F Flow: 3 / 20. Per the Roarable RQD rating, this pillar measures institutional accumulation and options positioning. Its low score indicates weak institutional support in the source data.
Insider Conviction: 5 / 20. Per the Roarable RQD rating, this pillar covers SEC Form 4 and Congressional PTR cluster flow. The low score indicates limited insider conviction signals.
Macro Regime Fit: 9 / 20. Per the Roarable RQD rating, beta is 1.0 with sector sensitivity noted. This is the highest-scoring pillar, but it still reflects only moderate alignment with macro conditions.
Forensic Balance Sheet: 10 / 20. Per the Roarable RQD rating, Altman Z is 2.5, Piotroski F is 2/9, and Debt/Equity is 0.5. These figures point to a stressed balance sheet with weak quality signals.

Taken together, the rating frames CLDI as a high-risk, pre-revenue biotech with weak cash generation, limited institutional and insider conviction, and forensic warning signs. The upside case depends on developments outside the reported financials, and the source data does not establish timing or probability for any such development. Per the market data, the stock trades at $0.67 against a 52-week range of $0.62 - $27.04, a level that reflects heavy price deterioration over the period.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$0.0M	$-20.2M	$-19.9M	N/A	$-21.3M	N/A	N/A
FY 2024	$0.0M	$-21.8M	$-22.1M	N/A	$-19.7M	$9.6M	N/A
FY 2023	$0.0M	$-29.0M	$-29.2M	N/A	$-27.0M	N/A	N/A

Per the SEC financials, the company reported operating losses and negative free cash flow in each period shown, with no reported revenue. Per the market data, gross, operating, and net margins are each 0%, and ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 2/9, with Debt/Equity at 0.5. Cash is reported only for FY 2024 at $9.6M; debt is not available in source data for any period.

Recent Catalysts & News Wire Analysis

Market wire (Yahoo Finance, flagged YELLOW): A headline "Stock Splits Calendar for:" is listed with no further detail in the source data.
Pipeline catalyst (GlobeNewswire, flagged YELLOW): Per the news feed, Calidi plans to present new CLD-401 data and in situ TCE platform advances at the ESMO Congress 2026. The source data does not describe the content or outcome of these data.
Market-action catalyst (TradingKey, flagged GREEN): A headline lists CLDI among top U.S. stock gainers. The source data does not specify the size or cause of the move.
Earnings item (flagged GREEN): A headline reports a Q4 2025 loss of $6.88 per share, described as narrower than expected against a pre-revenue backdrop. The source attribution for this item is a non-descriptive domain, so treat it with caution.

Per the Butterfly Supply-Chain Graph, no supply-chain links or proprietary signals are present.

Open Questions

What are the specific data outcomes and timing for CLD-401 and the in situ TCE platform, and what is the source data's basis for the ESMO presentation?
What is the company's cash position and debt load for FY 2025, given that cash and debt are N/A in the reported financials?
What drove the 52-week decline from $27.04 to $0.62, and does it relate to listing, financing, or clinical developments?
What is the company's funding runway relative to its annual operating losses of roughly $20M to $29M?
Why is the EPS field N/A across all reported periods, and what is the current share count?

CLDI Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Calidi Biotherapeutics Inc. (CLDI) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to CLDI Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 13h ago

Stock Splits Calendar for:

Yahoo Finance report covering Calidi Biotherapeutics Inc. (CLDI) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE GlobeNewswire • 16h ago

Calidi Biotherapeutics to Present New CLD-401 Data and In Situ TCE Platform Advances at the ESMO Congress 2026

GlobeNewswire report covering Calidi Biotherapeutics Inc. (CLDI) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST TradingKey • 19h ago

Top U.S. Stock Gainers: Biggest Price Increases

TradingKey report covering Calidi Biotherapeutics Inc. (CLDI) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST https://www.dars.gov.et/ • 22h ago

CLDI Q4 2025 Earnings: Narrower-Than-Expected Loss of $6.88 Per Share Against a Pre-Revenue Backdrop

https://www.dars.gov.et/ report covering Calidi Biotherapeutics Inc. (CLDI) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo • 6d ago

Calidi Biotherapeutics Presented New CLD-401 Data and In Situ TCE Platform Advances at the ESMO Congress 2026, Including Highlighting the Potential of its RedTail Gene Medicine Platform to Turn Tumors into Localized TCE Biofactories

Single-dose CLD-401 induced tumor regression and complete response in 80% of mice in EMT6 breast tumor model Building on the growing clinical evidence supporting T-cell engagers in solid tumors, data showed the platform

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 6d ago

Calidi Biotherapeutics Reports Two Posters At European Society For Medical Oncology From Its RedTail Platform

Calidi Biotherapeutics, Inc. (NYSE American: CLDI) ("Calidi" or "the Company"), a biotechnology company pioneering the development of targeted genetic medicines, announced that it presented two posters

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 14d ago

Calidi Biotherapeutics To Present Preclinical Data On CLD-401 And In Situ T-Cell Engager Programs At ESMO 2026, Highlighting Tumor Eradication And Antitumor Activity Findings

Calidi Biotherapeutics, Inc. (NYSE:CLDI) ("Calidi" or "the Company"), a biotechnology company pioneering the development of targeted genetic medicines, announced that it will be presenting two posters at

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

CLDI Bull vs. Bear Conversation Board — What's Your Call at $0.69?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON CLDI 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $0.59 (-11.9%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is CLDI (E • RQD 31/100) a Buy at $0.67?

Welcome to the CLDI (Calidi Biotherapeutics Inc.) Roar Pit. Current RQD Composite is 31/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

SK SkepticalCFA Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $0.54 (-19.4%)

Spot @ $0.67

Pump the brakes on CLDI — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on CLDI, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Calidi Biotherapeutics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

CA CashFlowKing Verified K Arena Trader 🐂 BULLISH 🎯 Target: $0.78 (+16.4%)

Spot @ $0.67

CLDI cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on CLDI, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $0.67 (52-wk range $0.62 - $27.04), any beat on forward guidance forces shorts and underweight funds to chase.